For patients in pre- and early-malignant disease stages, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma, current guidelines recommend monitoring disease progression through watchful waiting. However, intervening earlier in the disease process may improve treatment outcomes for patients that eventually do progress to symptomatic high-risk multiple myeloma. Our Moon Shot experts are focused on improving the identification of patients at high-risk for progression and evaluating the ability for immunotherapy to delay, or prevent, progression in these patients.